Please login to the form below
BeiGene
This page shows the latest BeiGene news and features for those working in and with pharma, biotech and healthcare.
Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn
The two companies are already working together after Novartis signed an in-licensing agreement for BeiGene’s anti-PD-1 monoclonal antibody, tislelizumab. ... need them across parts of China,” said John Oyler, co-founder, CEO and chairman of BeiGene.
Latest news
-
BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial
In the ORR analysis conducted by the independent review committee (IRC), BeiGene’s drug demonstrated non-inferiority in the interim analysis. ... consistent safety advantages for these patients,” said Jane Huang, chief medical officer, Haematology at
-
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
Detailed results from the study will be presented at an upcoming medical conference, BeiGene said in a statement. ... In April, BeiGene also unveiled results from a key global trial of tislelizumab in non-small cell lung cancer (NSCLC).
-
FDA priority review granted for BeiGene’s Brukinsa for marginal zone lymphoma
In China, BeiGene’s is approved for pretreated MCL patients as well as pretreated chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) patients. ... BeiGene revealed in a statement that the FDA has set a prescription drug user fee
-
BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC
At 12 months, the PFS rate was 23.3% for patients receiving BeiGene/Novartis’ therapy versus 5.7% in the docetaxel arm. ... added. In January, Novartis and BeiGene signed a strategic collaboration agreement for the Swiss pharma company to in-license
-
Merck expands partnership with Zymeworks for multispecific antibodies
Chinese pharma BeiGene also owns the rights to Zanidatamab and ZW49 in a number of East Asian countries including China and South Korea as well as Australia and New Zealand.
More from news
Approximately 15 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
BeiGene says it as headed off any such concens by working with well-established pharma company and contract manufacturer Boehringer Ingelheim to manufacture its drug. ... Meanwhile, BeiGene is also looking to break into the still all-important US market.
-
Biopharma's Future: Made in China
The rise of Chinese biopharma. One home-grown pharma company which could replicate this accomplishment is Beijing-headquartered BeiGene. ... BeiGene’s CEO John Oyler told a Goldman Sachs recent conference that a Chinese biopharma sector was ready to
-
Deal Watch March 2017
In particular, the third largest deal of the month is a joint venture between the research-based biotechnology company, BeiGene, which focuses on immuno-oncology, and the Guangzhou Development District. ... The agreement, worth $330m, will build BeiGene
-
Deal Watch table for November 2013
BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.
More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest appointments
-
New hires at EMA, Gilead and BeiGene
EMA gains a new executive director, Gilead appoints a new senior vice president and BeiGene hires a new chief business exec. ... BeiGene. BeiGene has appointed Angus Grant (pictured above) as chief business executive.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
